This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Adam's Most Recent Article

MannKind's Afrezza Lags Behind Biggest Failure in Inhaled Insulin

06/30/15 - 11:27 AM EDT

The number of prescriptions written for MannKind's inhaled insulin drug Afrezza are barely making a dent in the diabetes market five months after partner Sanofi launched the product.

read more >

Other Articles by Adam

Free Reports

Celgene is Desperate or Insane to Pay Ultra-High Premium for Juno Partnership

06/29/15 - 05:10 PM EDT

Under terms of the 10-year collaboration, Celgene is buying 9.1 million shares of Juno at $93 per share -- a 102% premium to Juno's closing price of $46.30.

read more >
Vertex Profits Hinge on FDA Approving New Cystic Fibrosis Drug This Week

06/29/15 - 11:06 AM EDT

Vertex Pharmaceuticals is widely expected to win U.S. approval later this week for a new drug which could one day treat almost half of cystic fibrosis patients.

read more >
Sarepta Submits DMD Drug for FDA Approval Review

06/29/15 - 07:02 AM EDT

New Sarepta CEO Ed Kaye filed for approval of eteplirsen with the FDA as promised, allowing him to check off a hugely important item on the company's to-do list.

read more >
Biotech Stock Mailbag: Exelixis, Puma Bio

06/26/15 - 06:01 AM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
Alcobra Placebo Beats Drug in Failed Genetic Disease Study

06/24/15 - 10:13 AM EDT

Alcobra's MDX has now failed to demonstrate benefit for patients in two different clinical trials.

read more >
Agenus Gets Billion-Dollar Valuation From Analyst Based on Cancer Drug That Doesn't Exist

06/23/15 - 12:53 PM EDT

We've reached the stage of the biotech bull market where a sell-side analyst can value a company on sales of a cancer drug that doesn't even exist.

read more >
Biotech Stock Mailbag: Unstoppable Heron, Aerie Disclosure Fail, Gene Therapy, Hate Mail!

06/19/15 - 06:00 AM EDT

Biotech columnist Adam Feuerstein answers readers' questions about health care.

read more >
Receptos Analyst Defends Company but Sounds Confused

06/18/15 - 08:52 AM EDT

I have some beefs with Leerink Partners biotech analyst Joe Schwartz and his research note in which he attempted to rebut my story about Receptos and the rampant takeout speculation.

read more >
Synergy Rises on Positive Results from Constipation Drug Study

06/17/15 - 11:58 AM EDT

Synergy Pharmaceuticals' experimental drug plecanatide significantly reduced chronic constipation compared to a placebo, achieving the primary goal of a late-stage study.

read more >
Page 1 of 337
< Previous
Top Rated Stocks Top Rated Funds Top Rated ETFs